Consolidation treatment with dexamethasone and alpha-2B recombinant interferon further reduces the M-component level in multiple myeloma patients responding to conventional induction chemotherapy

Palumbo, A.P.; Garino, A.L.; Frieri, R.; Gallone, G.; Boccadoro, M.; Pileri, A.

Haematologica 75(6): 576-578


ISSN/ISBN: 0390-6078
PMID: 2098302
Document Number: 366989
Three patients with symptomatic multiple myeloma who had achieved an objective response after conventional induction chemotherapy were treated with alpha-2b-interferon plus intermittent high-dose dexamethasone as consolidation therapy. This treatment included three mega units of alpha-2b-interferon three times a week, plus 4 days pulsed high-dose dexamethasone every 28 days for 6 months. Toxicity was limited to a mild flu-like syndrome. A further and significant M-component reduction (50%), obtained after conventional chemotherapy, suggests the value of intermittent high-dose dexamethasone plus interferon as consolidation therapy.

Document emailed within 1 workday
Secure & encrypted payments